AustralianSuper Pty Ltd Sells 31,588 Shares of Solventum Corporation $SOLV

AustralianSuper Pty Ltd lowered its stake in Solventum Corporation (NYSE:SOLV) by 25.4% in the second quarter, Holdings Channel reports. The fund owned 92,985 shares of the company’s stock after selling 31,588 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Solventum were worth $7,052,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in SOLV. Independent Franchise Partners LLP increased its position in Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock worth $442,608,000 after purchasing an additional 4,217,570 shares in the last quarter. Davis Selected Advisers grew its stake in shares of Solventum by 0.8% during the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock worth $402,110,000 after buying an additional 41,524 shares during the last quarter. Boston Partners increased its holdings in shares of Solventum by 101.3% during the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock worth $255,554,000 after buying an additional 1,691,565 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Solventum by 3.3% in the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after acquiring an additional 58,373 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Solventum by 2.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock valued at $89,268,000 after acquiring an additional 24,762 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV stock opened at $72.08 on Tuesday. The stock has a market capitalization of $12.50 billion, a PE ratio of 33.37, a PEG ratio of 2.91 and a beta of 0.50. The business’s 50 day simple moving average is $72.64 and its 200 day simple moving average is $72.24. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same quarter in the previous year, the company earned $1.56 EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on SOLV. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Solventum in a research note on Wednesday, October 8th. Jefferies Financial Group started coverage on shares of Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price on the stock. UBS Group started coverage on shares of Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target for the company. Finally, Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target for the company in a research note on Tuesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Solventum has an average rating of “Hold” and a consensus target price of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.